Genetic association studies of methamphetamine use disorders: A systematic review and synthesis

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 150, Issue 8, 2009, Pages 1025-1049

  Bousman, Chad A ^a,b   Glatt, Stephen J ^c   Everall, Ian P ^a   Tsuang, Ming T ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN DIEGO STATE UNIVERSITY   (United States)

^c State University of New York Upstate Medical University: College of Medicine   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Dependence; Gene association; Methamphetamine; Psychosis; Review

Indexed keywords

METHAMPHETAMINE;

AKT1 GENE; ARRB2 GENE; BDNF GENE; COMT GENE; CYP2D6 GENE; DRDR4 GENE; DRUG DEPENDENCE; DTNBP1 GENE; GABRA1 GENE; GABRG2 GENE; GENE; GENE LOCATION; GENETIC ASSOCIATION; GLYT1 GENE; GSTM1 GENE; GSTP1 GENE; HERITABILITY; HUMAN; OPRM1 GENE; PDYN GENE; PHENOTYPE; PICK1 GENE; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SLC22A3 GENE; SNCA GENE; SOD2 GENE; SUBSTANCE ABUSE; SYSTEMATIC REVIEW;

AMPHETAMINE-RELATED DISORDERS; GENETIC ASSOCIATION STUDIES; HUMANS; METHAMPHETAMINE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 72049103940     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30936     Document Type: Review

References (151)

1. American Psychiatric Association. 1994. Diagnostic criteria from DSM-IV. Washington, DC: The Association. p. 358.
2. Anglin MD, Burke C, Perrochet B, Stamper E, Dawud-Noursi S. 2000. History of the methamphetamine problem. J Psychoactive Drugs 32:137-141.
3. Aoyama N, Takahashi N, Kitaichi K, Ishihara R, Saito S, Maeno N, Ji X, Takagi K, Sekine Y, Iyo M, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Iwata N, Inada T, Ozaki N. 2006. Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. Alcohol Clin Exp Res 30:1644-1649. (Pubitemid 44465604)
4. Barr AM, Panenka WJ, MacEwan GW, Thornton AE, Lang DJ, Honer WG, Lecomte T. 2006. The need for speed: An update on methamphetamine addiction. J Psychiatry Neurosci 31:301-313. (Pubitemid 44497427)
5. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. 2005. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261-273. (Pubitemid 41032989)
6. Beaulieu JM, Gainetdinov RR, Caron MG. 2007. The akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 28:166-172.
7. Bell DS. 1965. Comparison of amphetamine psychosis and schizophrenia. Br J Psychiatry 111:701-707.
8. Benson MA, Newey SE, Martin-Rendon E, Hawkes R, Blake DJ. 2001. Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. J Biol Chem 276:24232-24241. (Pubitemid 37410830) (Pubitemid 33654314)
9. Benson MA, Sillitoe RV, Blake DJ. 2004. Schizophrenia genetics: Dysbindin under the microscope. Trends Neurosci 27:516-519.
10. Berrettini WH, Lerman CE. 2005. Pharmacotherapy and pharmacogenetics of nicotine dependence. Am J Psychiatry 162:1441-1451.
11. Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau OF, Swan GE, Rutter J, Bertelsen S, Fox L, Fugman D, Goate AM, Hinrichs AL, Konvicka K, Martin NG, Montgomery GW, Saccone NL, Saccone SF, Wang JC, Chase GA, Rice JP, Ballinger DG. 2007. Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet 16:24-35. (Pubitemid 46152542)
12. Bolanos CA, Nestler EJ. 2004. Neurotrophic mechanisms in drug addiction. Neuromolecular Med 5:69-83.
13. Bonci A, Hopf FW. 2005. The dopamine D2 receptor: New surprises from an old friend. Neuron 47:335-338. (Pubitemid 41073875)
14. Bonsch D, Lederer T, Reulbach U, Hothorn T, Kornhuber J, Bleich S. 2005. Joint analysis of the NACP-REP1 marker within the alpha synuclein gene concludes association with alcohol dependence. Hum Mol Genet 14:967-971. (Pubitemid 40533107)
15. Bruder GE, Keilp JG, Xu H, Shikhman M, Schori E, Gorman JM, Gilliam TC. 2005. Catechol-O-methyltransferase (COMT) genotypes and working memory: Associations with differing cognitive operations. Biol Psychiatry 58:901-907. (Pubitemid 41790719)
16. Burri RJ, Stock RG, Cesaretti JA, Atencio DP, Peters S, Peters CA, Fan G, Stone NN, Ostrer H, Rosenstein BS. 2008. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat Res 170:49-59. (Pubitemid 351931187)
17. Burton PR, Tobin MD, Hopper JL. 2005. Key concepts in genetic epidemiology. Lancet 366:941-951.
18. Cadet JL, Sheng P, Ali S, Rothman R, Carlson E, Epstein C. 1994. Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J Neurochem 62:380-383. (Pubitemid 24010665) (Pubitemid 24976969)
19. Cadoret RJ, Troughton E, O'Gorman TW, Heywood E. 1986. An adoption study of genetic and environmental factors in drug abuse. Arch Gen Psychiatry 43:1131-1136. (Pubitemid 17184442)
20. Cadoret RJ, Yates WR, Troughton E, Woodworth G, Stewart MA. 1995. Adoption study demonstrating two genetic pathways to drug abuse. Arch Gen Psychiatry 52:42-52.
21. Calnan M, Smith GD, Sterne JA. 2006. The publication process itself was the major cause of publication bias in genetic epidemiology. J Clin Epidemiol 59:1312-1318. (Pubitemid 44708612)
22. Cantrell FL, Breckenridge HM, Jost P. 2006. Transrectal methamphetamine use: A novel route of exposure. Ann Intern Med 145:78-79. (Pubitemid 46780611)
23. Carlsten C, Sagoo GS, Frodsham AJ, Burke W, Higgins JP. 2008. Glutathione S-transferase M1 (GSTM1) polymorphisms and lung cancer: A literature-based systematic HuGE review and meta-analysis. Am J Epidemiol 167:759-774.
24. Chen AC, LaForge KS, Ho A, McHugh PF, Kellogg S, Bell K, Schluger RP, Leal SM, Kreek MJ. 2002. Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse. Am J Med Genet 114:429-435. (Pubitemid 34525241)
25. Chen CK, Hu X, Lin SK, Sham PC, Loh EW, Li T, Murray RM, Ball DM. 2004a. Association analysis of dopamine D2-like receptor genes and methamphetamine abuse. Psychiatr Genet 14:223-226. (Pubitemid 40054350)
26. Chen J, Lipska BK, Halim N, MaQD, Matsumoto M, Melhem S, Kolachana BS, Hyde TM, Herman MM, Apud J, Egan MF, Kleinman JE, Weinberger DR. 2004b. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): Effects onmRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75:807-821. (Pubitemid 39390488)
27. Chen CK, Lin SK, Huang MC, Su LW, Hsiao CC, Chiang YL, Ree SC, Chiang SC, Liu HC. 2007. Analysis of association of clinical correlates and 5-HTTLPR polymorphism with suicidal behavior among chinese methamphetamine abusers. Psychiatry Clin Neurosci 61:479-486.
28. Cheng CY, Hong CJ, Yu YW, Chen TJ, Wu HC, Tsai SJ. 2005. Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males. Brain Res Mol Brain Res 140:86-90.
29. Colhoun HM, McKeigue PM, Davey Smith G. 2003. Problems of reporting genetic associations with complex outcomes. Lancet 361:865-872.
30. Costa LG, Eaton DL. 2006. Gene-environment interactions: Fundamentals of ecogenetics. Hoboken, NJ: Wiley-Liss: p. 557.
31. Craddock N, Dave S, Greening J. 2001. Association studies of bipolar disorder. Bipolar Disord 3:284-298.
32. Daunais JB, Roberts DC, McGinty JF. 1993. Cocaine self-administration increases preprodynorphin, but not c-fos, mRNA in rat striatum. Neuroreport 4:543-546. (Pubitemid 23153985)
33. Davey Smith G, Ebrahim S, Lewis S, Hansell AL, Palmer LJ, Burton PR. 2005. Genetic epidemiology and public health: Hope, hype, and future prospects. Lancet 366:1484-1498. (Pubitemid 41483815)
34. Deken SL, Beckman ML, Quick MW. 2001. PICKing on transporters. Trends Neurosci 24:623-625.
35. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR. 2001. Effect of COMTVal108/158 met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98:6917-6922. (Pubitemid 32538317)
36. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. 2004. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36:131-137. (Pubitemid 38174370)
37. Gelernter J, Panhuysen C, Weiss R, Brady K, Hesselbrock V, Rounsaville B, Poling J, Wilcox M, Farrer L, Kranzler HR. 2005. Genomewide linkage scan for cocaine dependence and related traits: Significant linkages for a cocaine-related trait and cocaine-induced paranoia. Am J Med Genet Part B 136B:45-52. (Pubitemid 40917527)
38. Glatt SJ, Faraone SV, Tsuang MT. 2003. Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: Meta-analysis of case-control and family-based studies. Am J Psychiatry 160:469-476. (Pubitemid 41094254)
39. Glatt SJ, Bousman C, Wang RS, Murthy KK, Rana BK, Lasky-Su JA, Zhu SC, Zhang R, Li J, Zhang B, Li J, Lyons MJ, Faraone SV, Tsuang MT. 2007. Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. Drug Alcohol Depend 90:159-165. (Pubitemid 47299168)
40. Golimbet VE, Alfimova MV, Gritsenko IK, Ebstein RP. 2007. Relationship between dopamine system genes and extraversion and novelty seeking. Neurosci Behav Physiol 37:601-606.
41. Grove WM, Eckert ED, Heston L, Bouchard TJ Jr, Segal N, Lykken DT. 1990. Heritability of substance abuse and antisocial behavior: A study of monozygotic twins reared apart. Biol Psychiatry 27:1293-1304. (Pubitemid 20189977)
42. Grundemann D, Schechinger B, Rappold GA, Schomig E. 1998. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci 1:349-351.
43. Gynther LM, Carey G, Gottesman II, Vogler GP. 1995. A twin study of non-alcohol substance abuse. Psychiatry Res 56:213-220.
44. Harada S, Tachikawa H, Kawanishi Y. 2001. Glutathione S-transferase M1 gene deletion may be associated with susceptibility to certain forms of schizophrenia. Biochem Biophys Res Commun 281:267-271. (Pubitemid 32928147)
45. Hashimoto T, Hashimoto K, Matsuzawa D, Shimizu E, Sekine Y, Inada T, Ozaki N, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Iyo M. 2005. A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in japanese population. Am J Med Genet Part B 135B:5-9.
46. Hashimoto T, Hashimoto K, Miyatake R, Matsuzawa D, Sekine Y, Inada T, Ozaki N, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Iyo M. 2008. Association study between polymorphisms in glutathione-related genes and methamphetamine use disorder in a japanese population. Am J Med Genet Part B 147B:1040-1046.
47. Hattersley AT, McCarthy MI. 2005. What makes a good genetic association study? Lancet 366:1315-1323.
48. Hong CJ, Cheng CY, Shu LR, Yang CY, Tsai SJ. 2003. Association study of the dopamine and serotonin transporter genetic polymorphisms and methamphetamine abuse in chinese males. J Neural Transm 110:345-351.
49. Horowitz R, Kotler M, Shufman E, Aharoni S, Kremer I, Cohen H, Ebstein RP. 2000. Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study. Am J Med Genet 96:599-603. (Pubitemid 30751739)
50. Hosak L, Libiger J, Cizek J, Beranek M, Cermakova E. 2006. The COMT Val158Met polymorphism is associated with novelty seeking in czech methamphetamine abusers: Preliminary results. Neuro Endocrinol Lett 27:799-802. (Pubitemid 46138642)
51. Hurd YL, Brown EE, Finlay JM, Fibiger HC, Gerfen CR. 1992. Cocaine self-administration differentially alters mRNA expression of striatal peptides. Brain Res Mol Brain Res 13:165-170.
52. Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, Lindsay RM. 1991. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350:230-232. (Pubitemid 21912205)
53. Ide S, Kobayashi H, Tanaka K, Ujike H, Sekine Y, Ozaki N, Inada T, Harano M, Komiyama T, Yamada M, Iyo M, Ikeda K, Sora I. 2004. Gene polymorphisms of themuopioid receptor in methamphetamine abusers. Ann NY Acad Sci 1025:316-324. (Pubitemid 39643877)
54. Ide S, Kobayashi H, Ujike H, Ozaki N, Sekine Y, Inada T, Harano M, Komiyama T, Yamada M, Iyo M, Iwata N, Tanaka K, Shen H, Iwahashi K, Itokawa M, Minami M, Satoh M, Ikeda K, Sora I. 2006. Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms. Pharmacogenomics J 6:179-188. (Pubitemid 43811569)
55. Ikeda M, Iwata N, Suzuki T, Kitajima T, Yamanouchi Y, Kinoshiya Y, Sekine Y, Iyo M, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Inada T, Ozaki N. 2006. Positive association of AKT1 haplotype to japanese methamphetamine use disorder. Int J Neuropsychopharmacol 9:77-81. (Pubitemid 43068336)
56. Ikeda M, Ozaki N, Suzuki T, Kitajima T, Yamanouchi Y, Kinoshita Y, Kishi T, Sekine Y, Iyo M, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Inada T, Iwata N. 2007. Possible association of beta-arrestin 2 gene with methamphetamine use disorder, but not schizophrenia. Genes Brain Behav 6:107-112. (Pubitemid 46090337)
57. Inada T, Iijima Y, Uchida N, Maeda T, Iwashita S, Ozaki N, Harano M, Komiyama T, Yamada M, Sekine Y, Iyo M, Sora I, Ujikec H. 2004. No association found between the type 1 sigma receptor gene polymorphisms and methamphetamine abuse in the japanese population: A collaborative study by the japanese genetics initiative for drug abuse. Ann NY Acad Sci 1025:27-33.
58. Itoh K, Hashimoto K, Shimizu E, Sekine Y, Ozaki N, Inada T, Harano M, Iwata N, Komiyama T, Yamada M, Sora I, Nakata K, Ujike H, Iyo M. 2005. Association study between brain-derived neurotrophic factor gene polymorphisms and methamphetamine abusers in japan. Am J Med Genet B Neuropsychiatr Genet 132:70-73. (Pubitemid 40066199)
59. Iwata N, Inada T, Harano M, Komiyama T, Yamada M, Sekine Y, Iyo M, Sora I, Ujike H, Ozaki N. 2004. No association is found between the candidate genes of t-PA/plasminogen system and japanese methamphetamine-related disorder: A collaborative study by the japanese genetics initiative for drug abuse. Ann NY Acad Sci 1025:34-38. (Pubitemid 39643842)
60. Jacobs D, Silverstone T. 1986. Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychol Med 16:323-329. (Pubitemid 16119194)
61. Jakes R, Spillantini MG, Goedert M. 1994. Identification of two distinct synucleins from human brain. FEBS Lett 345:27-32. (Pubitemid 24154659)
62. Johnson C, Drgon T, Liu QR, Walther D, Edenberg H, Rice J, Foroud T, Uhl GR. 2006. Pooled association genome scanning for alcohol dependence using 104,268 SNPs: Validation and use to identify alcoholism vulnerability loci in unrelated individuals from the collaborative study on the genetics of alcoholism. Am J Med Genet Part B 141B:844-853. (Pubitemid 44905437)
63. Kanahara N, Miyatake R, Sekine Y, Inada T, Ozaki N, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Iyo M, Hashimoto K. 2008. Association study between the PIK4CA gene and methamphetamine use disorder in a japanese population. Am J Med Genet Part B[Epub ahead of print].
64. Kang D, Lee KM, Park SK, Berndt SI, Peters U, Reding D, Chatterjee N, Welch R, Chanock S, Huang WY, Hayes RB. 2007. Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. Cancer Epidemiol Biomarkers Prev 16:1581-1586. (Pubitemid 47294822)
65. Karayiorgou M, Altemus M, Galke BL, Goldman D, Murphy DL, Ott J, Gogos JA. 1997. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci USA 94:4572-4575. (Pubitemid 27194283)
66. Kendler KS, Prescott CA. 1998. Cocaine use, abuse and dependence in a population-based sample of female twins. Br J Psychiatry 173:345-350. (Pubitemid 28454823)
67. Kendler KS, Jacobson KC, Prescott CA, Neale MC. 2003. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry 160:687-695.
68. Kishimoto M, Ujike H, Motohashi Y, Tanaka Y, Okahisa Y, Kotaka T, Harano M, Inada T, Yamada M, Komiyama T, Hori T, Sekine Y, Iwata N, Sora I, Iyo M, Ozaki N, Kuroda S. 2008a.The dysbindin gene(DTNBP1) is associated withmethamphetamine psychosis.Biol Psychiatry 63:191-196.
69. Kishimoto M, Ujike H, Okahisa Y, Kotaka T, Takaki M, Kodama M, Inada T, Yamada M, Uchimura N, Iwata N, Sora I, Iyo M, Ozaki N, Kuroda S. 2008b. The frizzled 3 gene is associated with methamphetamine psychosis in the japanese population. Behav Brain Funct 4:37.
70. Kitanaka J, Kitanaka N, Takemura M. 2008. Neurochemical consequences of dysphoric state during amphetamine withdrawal in animal models: A review. Neurochem Res 33:204-219. (Pubitemid 50011268)
71. Kobayashi H, Ide S, Hasegawa J, Ujike H, Sekine Y, Ozaki N, Inada T, Harano M, Komiyama T, Yamada M, Iyo M, Shen HW, Ikeda K, Sora I. 2004. Study of association between alpha-synuclein gene polymorphism and methamphetamine psychosis/dependence. Ann NY Acad Sci 1025:325-334. (Pubitemid 39643878)
72. Kobayashi H, Hata H, Ujike H, Harano M, Inada T, Komiyama T, Yamada M, Sekine Y, Iwata N, Iyo M, Ozaki N, Itokawa M, Naka M, Ide S, Ikeda K, Numachi Y, Sora I. 2006. Association analysis of delta-opioid receptor gene polymorphisms in methamphetamine dependence/psychosis. Am J Med Genet Part B 141B:482-486. (Pubitemid 44024442)
73. Koizumi H, Hashimoto K, Kumakiri C, Shimizu E, Sekine Y, Ozaki N, Inada T, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Takei N, Iyo M. 2004. Association between the glutathione S-transferase M1 gene deletion and female methamphetamine abusers. Am J Med Genet Part B 126B:43-45. (Pubitemid 38420119)
74. Kreek MJ, Schluger J, Borg L, Gunduz M, Ho A. 1999. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: Gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. J Pharmacol Exp Ther 288:260-269. (Pubitemid 29113499)
75. Kulsudjarit K. 2004. Drug problem in southeast and southwest Asia. Ann NY Acad Sci 1025:446-457. (Pubitemid 39643893)
76. Levinson DF. 2006. The genetics of depression: A review. Biol Psychiatry 60:84-92.
77. Li T, Chen CK, Hu X, Ball D, Lin SK, Chen W, Sham PC, Loh EW, Murray RM, Collier DA. 2004. Association analysis of the DRD4 and COMT genes in methamphetamine abuse. Am J Med Genet Part B 129B: 120-124. (Pubitemid 38989081)
78. Lin LY, Di Stefano EW, Schmitz DA, Hsu L, Ellis SW, Lennard MS, Tucker GT, Cho AK. 1997. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos 25:1059-1064.
79. Lin SK, Chen CK, Ball D, Liu HC, Loh EW. 2003. Gender-specific contribution of the GABA(A) subunit genes on 5q33 in methamphetamine use disorder. Pharmacogenomics J 3:349-355. (Pubitemid 38072173)
80. Little J, Bradley L, Bray MS, Clyne M, Dorman J, Ellsworth DL, Hanson J, Khoury M, Lau J, O'Brien TR, Rothman N, Stroup D, Taioli E, Thomas D, Vainio H, Wacholder S, Weinberg C. 2002. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 156:300-310. (Pubitemid 34857997)
81. Liu HC, Lin SK, Liu SK, Chen SL, Hu CJ, Chang JG, Leu SJ. 2004. DAT polymorphism and diverse clinical manifestations in methamphetamine abusers. Psychiatr Genet 14:33-37.
82. Liu HC, Chen CK, Leu SJ, Wu HT, Lin SK. 2006a. Association between dopamine receptor D1 A-48G polymorphism and methamphetamine abuse. Psychiatry Clin Neurosci 60:226-231.
83. Liu QR, Drgon T, Johnson C, Walther D, Hess J, Uhl GR. 2006b. Addiction molecular genetics: 639,401 SNP whole genome association identifies many "cell adhesion" genes. Am J Med Genet Part B 141B:918-925.
84. Loh EW, Higuchi S, Matsushita S, Murray R, Chen CK, Ball D. 2000. Association analysis of the GABA(A) receptor subunit genes cluster on 5q33-34 and alcohol dependence in a japanese population. Mol Psychiatry 5:301-307. (Pubitemid 30438406)
85. Lu L, Fang Y, Wang X. 2008. Drug abuse in china: Past, present and future. Cell Mol Neurobiol 28:479-490.
86. Macmillan-Crow LA, Cruthirds DL. 2001. Invited review: Manganese superoxide dismutase in disease. Free Radic Res 34:325-336. (Pubitemid 32331659)
87. Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D. 2002. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 159:652-654. (Pubitemid 34274949)
88. Mamelak M. 1978. An amphetamine model of manic depressive illness. Int Pharmacopsychiatry 13:193-208. (Pubitemid 9050845)
89. Marcus DL, Strafaci JA, Freedman ML. 2006. Differential neuronal expression of manganese superoxide dismutase in alzheimer's disease. Med Sci Monit 12:BR8-BR14.
90. Matsuzawa D, Hashimoto K, Miyatake R, Shirayama Y, Shimizu E, Maeda K, Suzuki Y, Mashimo Y, Sekine Y, Inada T, Ozaki N, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Hata A, Sawa A, Iyo M. 2007. Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis. Am J Psychiatry 164:1105-1114. (Pubitemid 47121400)
91. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, Kolachana B, Callicott JH, Weinberger DR. 2003. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 100: 6186-6191. (Pubitemid 36576952)
92. Maxwell JC, Rutkowski BA. 2008. The prevalence of methamphetamine and amphetamine abuse in north america: A review of the indicators, 1992-2007. Drug Alcohol Rev 27:229-235.
93. McLellan RA, Oscarson M, Alexandrie AK, Seidegard J, Evans DA, Rannug A, Ingelman-Sundberg M. 1997. Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene that causes ultrarapid enzyme activity. Mol Pharmacol 52:958-965. (Pubitemid 28013713)
94. Millon T. 1991. Classification in psychopathology: Rationale, alternatives, and standards. J Abnorm Psychol 100:245-261.
95. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. 1998. Dopamine receptors: From structure to function. Physiol Rev 78:189-225.
96. Miura H, Fujiki M, Shibata A, Ishikawa K. 2006. Prevalence and profile of methamphetamine users in adolescents at a juvenile classification home. Psychiatry Clin Neurosci 60:352-357. (Pubitemid 43736401)
97. Morio A, Ujike H, Nomura A, Tanaka Y, Morita Y, Otani K, Kishimoto M, Harano M, Inada T, Komiyama T, Yamada M, Sekine Y, Iwata N, Iyo M, Sora I, Ozaki N, Kuroda S. 2006.Noassociation between CART (cocaineand amphetamine-regulated transcript) gene and methamphetamine dependence. Ann NY Acad Sci 1074:411-417. (Pubitemid 44532846)
98. Morita Y, Ujike H, Tanaka Y, Uchida N, Nomura A, Ohtani K, Kishimoto M, Morio A, Imamura T, Sakai A, Inada T, Harano M, Komiyama T, Yamada M, Sekine Y, Iwata N, Iyo M, Sora I, Ozaki N, Kuroda S. 2005a. A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia. Neurosci Lett 376:182-187. (Pubitemid 40255306)
99. Morita Y, Ujike H, Tanaka Y, Uchida N, Nomura A, Otani K, Kishimoto M, Morio A, Inada T, Harano M, Komiyama T, Yamada M, Sekine Y, Iwata N, Iyo M, Sora I, Ozaki N. 2005b. The X-box binding protein 1 (XBP1) gene is not associated with methamphetamine dependence. Neurosci Lett 383:194-198. (Pubitemid 40779981)
100. Morita Y, Ujike H, Tanaka Y, Kishimoto M, Okahisa Y, Kotaka T, Harano M, Inada T, Komiyama T, Hori T, Yamada M, Sekine Y, Iwata N, Iyo M, Sora I, Ozaki N, Kuroda S. 2008. The glycine transporter 1 gene (GLYT1) is associated with methamphetamine-use disorder. Am J Med Genet B Neuropsychiatr Genet 147B:54-58.
101. Munafo MR, Clark TG, Flint J. 2004. Assessing publication bias in genetic association studies: Evidence from a recent meta-analysis. Psychiatry Res 129:39-44. (Pubitemid 39574435)
102. Nakamura K, Chen CK, Sekine Y, Iwata Y, Anitha A, Loh EW, Takei N, Suzuki A, Kawai M, Takebayashi K, Suzuki K, Minabe Y, Tsuchiya K, Yamada K, Iyo M, Ozaki N, Inada T, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Ball DM, Yoshikawa T, Lin SK, Mori N. 2006. Association analysis of SOD2 variants with methamphetamine psychosis in japanese and Taiwanese populations. Hum Genet 120: 243-252. (Pubitemid 44204013)
103. National Drug Intelligence Center. 2006. National methamphetamine threat assessment 2007. Johnstown, PA:U.S. Dept. of Justice, National Drug. Intelligence Center. p. 23.
104. Nishiyama T, Ikeda M, Iwata N, Suzuki T, Kitajima T, Yamanouchi Y, Sekine Y, Iyo M, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Inada T, Furukawa T, Ozaki N. 2005. Haplotype association between GABAA receptor gamma2 subunit gene (GABRG2) and methamphetamine use disorder. Pharmacogenomics J 5:89-95. (Pubitemid 40468115)
105. Nomura A, Ujike H, Tanaka Y, Otani K, Morita Y, Kishimoto M, Morio A, Harano M, Inada T, Yamada M, Komiyama T, Sekine Y, Iwata N, Sora I, Iyo M, Ozaki N, Kuroda S. 2006. Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence. Neurosci Lett 400: 158-162.
106. Ohgake S, Hashimoto K, Shimizu E, Koizumi H, Okamura N, Koike K, Matsuzawa D, Sekine Y, Inada T, Ozaki N, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Shirayama Y, Iyo M. 2005. Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis. Addict Biol 10:145-148. (Pubitemid 40976383)
107. Oroszi G, Goldman D. 2004. Alcoholism: Genes and mechanisms. Pharmacogenomics 5:1037-1048.
108. Otani K, Ujike H, Sakai A, Okahisa Y, Kotaka T, Inada T, Harano M, Komiyama T, Hori T, Yamada M, Sekine Y, Iwata N, Iyo M, Sora I, Ozaki N, Kuroda S. 2008. Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence. Neurosci Lett 434: 88-92.
109. Pae CU, Yu HS, Kim JJ, Kim W, Lee CU, Lee SJ, Jun TY, Lee C, Paik IH, Serretti A. 2004. Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population. Psychiatr Genet 14:147-150. (Pubitemid 39281822)
110. Pfeiffer A, Brantl V, Herz A, Emrich HM.1986. Psychotomimesis mediated by kappa opiate receptors. Science 233:774-776. (Pubitemid 16016229)
111. Qian Q, Wang Y, Zhou R, Li J, Wang B, Glatt S, Faraone SV. 2003. Family-based and case-control association studies of catechol-O- methyltransferase in attention deficit hyperactivity disorder suggest genetic sexual dimorphism. Am J Med Genet Part B 118B:103-109. (Pubitemid 37064084)
112. Quinton MS, Yamamoto BK. 2006. Causes and consequences of methamphetamine and MDMA toxicity. AAPS J 8:E337-E347.
113. Rajaraman P, Hutchinson A, Rothman N, Black PM, Fine HA, Loeffler JS, Selker RG, Shapiro WR, Linet MS, Inskip PD. 2008. Oxidative response gene polymorphisms and risk of adult brain tumors. Neuro Oncol 10(5):709-715.
114. Rockman MV, Hahn MW, Soranzo N, Zimprich F, Goldstein DB, Wray GA. 2005. Ancient and recent positive selection transformed opioid cis-regulation in humans. PLoS Biol 3:e387. (Pubitemid 41796335)
115. Rosa A, Peralta V, Cuesta MJ, Zarzuela A, Serrano F, Martinez-Larrea A, Fananas L. 2004. New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. Am J Psychiatry 161:1110-1112. (Pubitemid 38735999)
116. Sato K, Adams R, Betz H, Schloss P. 1995. Modulation of a recombinant glycine transporter (GLYT1b) by activation of protein kinase C. J Neurochem 65:1967-1973.
117. Saxon AJ. 2006. Genetic determinants of addiction to alcohol, tobacco, and drugs of abuse. In: Costa LG, Eaton DL, editors. Gene-environment interactions: Fundamentals of ecogenetics. Hoboken, NJ:Wiley-Liss. p. 351.
118. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, Grant I. 2007. Neurocognitive effects of methamphetamine: A critical review and meta-analysis. Neuropsychol Rev 17:275-297. (Pubitemid 47498174)
119. Seltzer V, Tonge SR. 1975. Proceedings: Methylamphetamine withdrawal as a model for the depressive state: Antagonism of post-amphetamine depression by imipramine. J Pharm Pharmacol 27(Suppl2): 16P.
120. Sery O, Vojtova V, Zvolsky P. 2001. The association study of DRD2, ACE and AGT gene polymorphisms and metamphetamine dependence. Physiol Res 50:43-50. (Pubitemid 32233678)
121. Shippenberg TS, Rea W. 1997. Sensitization to the behavioral effects of cocaine: Modulation by dynorphin and kappa-opioid receptor agonists. Pharmacol Biochem Behav 57:449-455. (Pubitemid 27296756)
122. Smith KE, Borden LA, Hartig PR, Branchek T, Weinshank RL. 1992. Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron 8:927-935.
123. Snyder SH. 1973. Amphetamine psychosis: A "model" schizophrenia mediated by catecholamines. Am J Psychiatry 130:61-67.
124. Spina MB, Squinto SP, Miller J, Lindsay RM, Hyman C. 1992. Brainderived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: Involvement of the glutathione system. J Neurochem 59:99-106.
125. Suzuki A, Nakamura K, Sekine Y, Minabe Y, Takei N, Suzuki K, Iwata Y, Kawai M, Takebayashi K, Matsuzaki H, Iyo M, Ozaki N, Inada T, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Mori N. 2006. An association study between catechol-O-methyl transferase gene polymorphism and methamphetamine psychotic disorder. Psychiatr Genet 16:133-138. (Pubitemid 44491779)
126. Talbot K, Eidem WL, Tinsley CL, Benson MA, Thompson EW, Smith RJ, Hahn CG, Siegel SJ, Trojanowski JQ, Gur RE, Blake DJ, Arnold SE. 2004. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 113:1353-1363. (Pubitemid 39069934)
127. Torres GE, Yao WD, Mohn AR, Quan H, Kim KM, Levey AI, Staudinger J, Caron MG. 2001. Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron 30:121-134. (Pubitemid 32441681)
128. Town T, Schinka J, Tan J, Mullan M. 2000. The opioid receptor system and alcoholism: A genetic perspective. Eur J Pharmacol 410:243-248. (Pubitemid 32008147)
129. Tsai SJ. 2007. Increased central brain-derived neurotrophic factor activity could be a risk factor for substance abuse: Implications for treatment. Med Hypotheses 68:410-414.
130. Tsai SJ, Cheng CY, Shu LR, Yang CY, Pan CW, Liou YJ, Hong CJ. 2002. No association for D2 and D4 dopamine receptor polymorphisms and methamphetamine abuse in Chinese males. Psychiatr Genet 12:29-33.
131. Tsuang MT, Lyons MJ, Eisen SA, Goldberg J, True W, Lin N, Meyer JM, Toomey R, Faraone SV, Eaves L. 1996. Genetic influences on DSM-III-R drug abuse and dependence: Astudy of 3,372 twin pairs. Am J Med Genet 67:473-477. (Pubitemid 26322141) (Pubitemid 126457208)
132. Tsuang MT, Lyons MJ, Meyer JM, Doyle T, Eisen SA, Goldberg J, True W, Lin N, Toomey R, Eaves L. 1998. Co-occurrence of abuse of different drugs in men: The role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry 55:967-972. (Pubitemid 28506837)
133. Turchan J, Maj M, Przewlocka B, Przewlocki R. 2002. Effect of cocaine and amphetamine on biosynthesis of proenkephalin and prodynorphin in some regions of the rat limbic system. Pol J Pharmacol 54:367-372.
134. Uhl GR, Liu QR, Walther D, Hess J, Naiman D. 2001. Polysubstance abuse-vulnerability genes: Genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. Am J Hum Genet 69:1290-1300. (Pubitemid 33124211)
135. Uhl GR, Liu QR, Naiman D. 2002. Substance abuse vulnerability loci: Converging genome scanning data. Trends Genet 18:420-425. (Pubitemid 34874540)
136. Uhl GR, Drgon T, Liu QR, Johnson C, Walther D, Komiyama T, Harano M, Sekine Y, Inada T, Ozaki N, Iyo M, Iwata N, Yamada M, Sora I, Chen CK, Liu HC, Ujike H, Lin SK. 2008. Genome-wide association for methamphetamine dependence: Convergent results from 2 samples. Arch Gen Psychiatry 65:345-355. (Pubitemid 351342451) (Pubitemid 351787239)
137. Ujike H, Harano M, Inada T, Yamada M, Komiyama T, Sekine Y, Sora I, Iyo M, Katsu T, Nomura A, Nakata K, Ozaki N. 2003. Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenomics J 3:242-247. (Pubitemid 37160980)
138. United Nations Office on Drugs and Crime. 2007. World drug report 2007. Vienna:UN Office on Drugs and Crime.
139. Vandenbergh DJ, Rodriguez LA, Miller IT, Uhl GR, Lachman HM. 1997. High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. Am J Med Genet 74:439-442.
140. Vanyukov MM, Tarter RE. 2000. Genetic studies of substance abuse. Drug Alcohol Depend 59:101-123.
141. Venter JC, Olsen RW. 1986. Benzodiazepine GABA receptors and chloride channels: Structural and functional properties. New York:A.R. Liss. p. 351.
142. Wilcox AS, Warrington JA, Gardiner K, Berger R, Whiting P, Altherr MR, Wasmuth JJ, Patterson D, Sikela JM. 1992. Human chromosomal localization of genes encoding the gamma 1 and gamma 2 subunits of the gamma-aminobutyric acid receptor indicates that members of this gene family are often clustered in the genome. Proc Natl Acad Sci USA 89:5857-5861.
143. Williams NM, O'Donovan MC, Owen MJ. 2005. Is the dysbindin gene (DTNBP1) a susceptibility gene for schizophrenia? Schizophr Bull 31:800-805.
144. World Health Organization. 1992. ICD-10: International statistical classification of diseases and related health problems, 10th revision. Geneva:- World Health Organization.
145. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V. 1998. Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem 273: 32776-32786. (Pubitemid 28557664)
146. Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA. 2002. Dopamine-dependent neurotoxicity of alpha-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8:600-606. (Pubitemid 34633438)
147. Yoon SJ, Pae CU, Lee H, Choi B, Kim TS, Lyoo IK, Kwon DH, Kim DJ. 2005. Ghrelin precursor gene polymorphism and methamphetamine dependence in the Korean population. Neurosci Res 53:391-395. (Pubitemid 41643066)
148. Yu Y, Kranzler HR, Panhuysen C, Weiss RD, Poling J, Farrer LA, Gelernter J. 2008. Substance dependence low-density whole genome association study in two distinct American populations. Hum Genet 123:495-506.
149. Zhang H, Luo X, Kranzler HR, Lappalainen J, Yang BZ, Krupitsky E, Zvartau E, Gelernter J. 2006. Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum Mol Genet 15:807-819. (Pubitemid 43338224)
150. Zimprich A, Kraus J, Woltje M, Mayer P, Rauch E, Hollt V. 2000. An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression. J Neurochem 74:472-477. (Pubitemid 30053718)
151. Zintzaras E, Lau J. 2008. Trends in meta-analysis of genetic association studies. J Hum Genet 53:1-9.